A similar result was obtained when the B16 melanoma model was used (Supplemental Figure 8H), further supporting our conclusion that ATXN3 inhibition enhances checkpoint blockade therapy even with suboptimal anti–PD-1 treatment. This evidence concerns the gene ATXN3 and melanoma.